Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

222,508 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy.
Schaer DA, Geeganage S, Amaladas N, Lu ZH, Rasmussen ER, Sonyi A, Chin D, Capen A, Li Y, Meyer CM, Jones BD, Huang X, Luo S, Carpenito C, Roth KD, Nikolayev A, Tan B, Brahmachary M, Chodavarapu K, Dorsey FC, Manro JR, Doman TN, Donoho GP, Surguladze D, Hall GE, Kalos M, Novosiadly RD. Schaer DA, et al. Among authors: li y. Clin Cancer Res. 2019 Dec 1;25(23):7175-7188. doi: 10.1158/1078-0432.CCR-19-0433. Epub 2019 Aug 13. Clin Cancer Res. 2019. PMID: 31409612
Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models.
Li Y, Amaladas N, O'Mahony M, Manro JR, Inigo I, Li Q, Rasmussen ER, Brahmachary M, Doman TN, Hall G, Kalos M, Novosiadly R, Puig O, Pytowski B, Schaer DA. Li Y, et al. Among authors: li q. PLoS One. 2022 Jul 18;17(7):e0268244. doi: 10.1371/journal.pone.0268244. eCollection 2022. PLoS One. 2022. PMID: 35849586 Free PMC article.
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.
Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amaladas N, Li Y, Wang YC, Rasmussen ER, Chin D, Capen A, Carpenito C, Staschke KA, Chung LA, Litchfield LM, Merzoug FF, Gong X, Iversen PW, Buchanan S, de Dios A, Novosiadly RD, Kalos M. Schaer DA, et al. Among authors: li y. Cell Rep. 2018 Mar 13;22(11):2978-2994. doi: 10.1016/j.celrep.2018.02.053. Cell Rep. 2018. PMID: 29539425 Free article.
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
Holmgaard RB, Schaer DA, Li Y, Castaneda SP, Murphy MY, Xu X, Inigo I, Dobkin J, Manro JR, Iversen PW, Surguladze D, Hall GE, Novosiadly RD, Benhadji KA, Plowman GD, Kalos M, Driscoll KE. Holmgaard RB, et al. Among authors: li y. J Immunother Cancer. 2018 Jun 4;6(1):47. doi: 10.1186/s40425-018-0356-4. J Immunother Cancer. 2018. PMID: 29866156 Free PMC article.
222,508 results
You have reached the last available page of results. Please see the User Guide for more information.